Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind phase 3 study of tadalafil in children with pulmonary arterial hypertension
MOH_2017-03-16_000213Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and adverse events and Efficacy of tadalafil in pediatric pulmonary arterial hypertension. Started Sep 2013; status: active, not recruiting.
02
Drugs
tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-03-16_000213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-16_000213.